Classen Johannes, Hehr Thomas, Lamprecht Ulf, Zumbrägel Andreas, Bamberg Michael, Budach Wilfried
Department of Radiation Oncology, Tübingen, Germany.
Strahlenther Onkol. 2003 Feb;179(2):118-22. doi: 10.1007/s00066-003-0998-z.
Radical surgery is the treatment of first choice for retroperitoneal sarcoma. However, locoregional relapse is frequently observed leading to death in the majority of patients. The role of radiotherapy is not well defined in the management of retroperitoneal sarcoma. Yet, there is evidence that adjuvant irradiation does improve local tumor control.
In order to deliver sufficiently high radiation doses to the retroperitoneum, different techniques for application of a local tumor boost dose in addition to external beam treatment have been proposed. We present a technique of hyperfractionated (192)Ir brachytherapy (HFIR) of the tumor bed via intraoperatively implanted plastic catheters. Postoperative CT-based image-guided brachytherapy was performed. In two consecutive patients with recurrent retroperitoneal sarcoma, treatment was delivered twice daily with single doses of 1.5-2.0 Gy in 5-10 mm tissue depth up to a total dose of 18-32.5 Gy.
HFIR of the tumor bed was easily accomplished facilitating delivery of high radiation doses to the retroperitoneum. No major late effects of treatment have been observed with a follow-up of 15 and 28 months, respectively. Details of the brachytherapy procedure are presented.
HFIR via intraoperatively implanted catheters in the retroperitoneum is a technique suitable for application of a local tumor boost dose. Thus, sufficiently high doses of radiation mandatory for long-lasting local tumor control can be delivered in the tumor bed of the retroperitoneum without exceeding normal tissue radiotolerance in this unfavorable disease.
根治性手术是腹膜后肉瘤的首选治疗方法。然而,局部区域复发很常见,导致大多数患者死亡。放疗在腹膜后肉瘤的治疗中的作用尚未明确界定。然而,有证据表明辅助放疗确实能改善局部肿瘤控制。
为了向腹膜后给予足够高的辐射剂量,除了外照射治疗外,还提出了不同的局部肿瘤增敏剂量应用技术。我们介绍一种通过术中植入塑料导管对肿瘤床进行超分割(192)铱近距离放疗(HFIR)的技术。进行了基于术后CT的图像引导近距离放疗。在两名连续的复发性腹膜后肉瘤患者中,每天进行两次治疗,在5-10毫米组织深度给予单剂量1.5-2.0 Gy,总剂量达18-32.5 Gy。
肿瘤床的HFIR很容易完成,便于向腹膜后给予高辐射剂量。分别随访15个月和28个月,未观察到治疗的重大晚期效应。介绍了近距离放疗程序的细节。
通过术中植入导管在腹膜后进行HFIR是一种适用于应用局部肿瘤增敏剂量的技术。因此,在这种预后不良的疾病中,在腹膜后肿瘤床可以给予足够高的辐射剂量以实现持久的局部肿瘤控制,而不会超过正常组织的放射耐受性。